background: breast cancer is one of the most common malignancies among iranian women; however, its clinicopathological feature is uncertain. we pioneered a genetic counseling program among patients with breast cancer and their families in isfahan. this is the first report of this program. methods: this was a descriptive cross-sectional study on women with breast cancer registered in ala cancer ...

Whereas the Her2/neu/erbB2 receptor (Her2) could be a molecular target of the receptor-positive breast cancer, the therapeutic targets of Her2-negative cancer largely remain to be established. The expression of Her2 was evaluated in 48 primary breast cancer tumors by immunohistochemistry. The identified Notch pathway was studied in genotoxin-dependent suppression of breast cancer-initiating cel...

Estrogen receptor function can drive cyclin D1 expression and proliferation in human breast cancer cells (MCF-7). Recent studies showing that estrogen receptor-positive epithelial cells in the human mammary gland are nonproliferative suggest that the direct mitogenic effect of estrogen on mammary epithelial cells may be acquired during breast cancer development. Because estrogen-dependent cycli...

background: malignant neoplastic lesions of the breast are one of the main causes of cancer death among women. several factors can be influential in the treatment process of breast cancer patients. the expression status of estrogen and progesterone receptors in tumor cells is among the most important determinants affecting the treatment approach and prognosis of these patients. in this paper, w...

background: il-10 is an anti-inflammatory cytokine which is involved in tumorigenesis. over production of il-10 and elevated number of il-10 generating mononuclear cells in breast tumor tissue has already been shown. objective: to determine the association of il-10 promoter polymorphisms with increased risk of breast cancer and its association with breast cancer prognostic factors. methods: per...

  Introduction: Over expression of selected peptide receptors in human tumors has been shown to represent clinically relevant targets for cancer diagnosis and therapy. The aim of this work was to investigate Neuropeptide Y (NPY) as a new radiopharmaceutical for diagnosis of breast cancer. Methods: A neuropeptide Y analogues with Y1 receptor preference and agonistic p...

Targeting the human epidermal growth factor receptor-2 (HER2) is cornerstone of treatment HER2+ breast cancer patients. The mechanism action trastuzumab partly based on lysis tumor cells via antibody dependent cellular cytotoxicity (ADCC), which among others involves NK cells. However, cell and CD8+ T-cell activity inhibited by binding inhibitory receptor NKG2A to HLA-E. HLA-E expression upregu...

The receptor interacting protein 140 (RIP140) belongs to a unique subclass of nuclear receptor coregulators with the ability to bind and repress the action of a number of agonist-bound hormone receptors. We have previously demonstrated that all-trans-retinoic acid (RA) induction of RIP140 constitutes a rate-limiting step in the regulation of retinoid receptor signaling. Here we demonstrate that...

Epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2/neu), members of the ErbB receptor tyrosine kinase family, are frequently overexpressed in breast cancer and are known to drive tumor growth and progression, making them promising targets for cancer therapy. Lapatinib is a selective competitive inhibitor of both the HER2 and EGFR tyrosine kinases. Although lapatinib showed significan...